Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Afa5.0
Afamelanotide – Forschung
Überwiegend Mechanismus / Beobachtung
20 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Afamelanotide sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen randomisierten Studien, veröffentlicht 2010–2026 mit einer typischen Studiengröße von 70 Teilnehmenden.
Basierend auf 20 Studien · 2 RCTs · 833 Teilnehmende insgesamt
Konfidenz
Geringe Konfidenz
Nach Outcome
Photoprotection & EPP
Überwiegend Mechanismus / Beobachtung14 Studien
Skin pigmentation & vitiligo
Überwiegend Mechanismus / Beobachtung8 Studien
Safety & melanocytic risk
Überwiegend Mechanismus / Beobachtung7 Studien
Aktives Forschungsgebiet
12 Studien in den letzten 5 Jahren
201020182026
1RCTn=168 · medium study2015
Afamelanotide... was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria.
Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, et al. · N Engl J Med (2015)
Two multicenter, randomized, double-blind, placebo-controlled Phase 3 trials of 16 mg subcutaneous afamelanotide implants every 60 days (EU n=74, US n=94)
Primary endpoint (pain-free hours of direct sunlight) was significantly longer with afamelanotide in both trials (US: 69.4 vs 40.8 h, P=0.04; EU: 6.0 vs 0.8 h, P=0.005)
Fewer phototoxic reactions (EU: 77 vs 146, P=0.04) and improved quality of life in both trials
Regulatory frameworks and dermatologic guidance must evolve to reflect the expanding landscape of sunless tanning modalities.
Resnick G, Khajeh-Afzaly M, Yousefian F, Raza A, Issa NT. · The Journal of clinical and aesthetic dermatology (2026)
Conclusion Sunless tanning agents offer UV-free alternatives for cosmetic pigmentation but are not without risk.
While DHA and melanotan remain the dominant agents in current use, forskolin and carotenoids offer alternative pathways for pigmentation and photoprotection.
Further clinical studies are necessary to evaluate long-term safety, efficacy across skin types, and formulation optimization.
3Systematische Übersicht2026
Moreover, to ensure benefit for patients and access to therapy after regulatory approval, it also would be important to generate data on the relative safety and efficacy as compared to afamelanotide.
Barman-Aksözen J, Granata F, Wäscher S, Falchetto R, Dechant C. · Expert opinion on pharmacotherapy (2026)
Areas covered This narrative review (using Pubmed and trial databases) aims to provide an overview of the status of development of dersimelagon and bitopertin, with a focus on the prevention of phototoxicity.
Expert opinion The currently available trial data on dersimelagon and bitopertin suggests treatment effects in EPP as compared to placebo control groups.
However, safety and efficacy of dersimelagon and bitopertin need to be further characterized.
Conclusion The advent of treatment modalities like Janus kinase inhibitors, prostaglandin analogues, antioxidants, TNF-α inhibitors, targeted phototherapy, and excimer lasers has revolutionized the therapeutic possibilities, offering a ray of hope to the individuals suffering from this devastating condition.
Ismail IB, Bhat YJ, Ul Islam MS. · Dermatology practical & conceptual (2025)
Methodology This review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Metanalyses) guidelines.
Two independent reviewers screened titles, abstracts, and full texts to select papers dealing with vitiligo and its treatment.
These advances must now be widely communicated and translated into equitable access for children across Europe.
Toenne M, Schaefer T. · European journal of pediatrics (2025)
Despite characteristic features, diagnosis is often delayed due to low awareness in paediatric care.
What is New: • This mini-review proposes a practical diagnostic algorithm for paediatric primary care and highlights key clinical clues to sensitise general paediatricians to EPP.
It also reviews emerging treatment options such as afamelanotide, already approved for adults, with promising adolescent data.
Afamelanotide, an alpha-melanocyte-stimulating hormone analogue, is currently the only approved specific treatment that increases pain-free sunlight exposure and quality of life.
Minder AE, Kluijver LG, Barman-Aksözen J, Minder EI, Langendonk JG. · Liver international : official journal of the International Association for the Study of the Liver (2025)
Because of its rarity, there is little data on the management of EPP-related liver disease.
As a first measure, any hepatotoxins should be eliminated.
Depending on the severity of the liver disease, phlebotomies, exchange transfusions and ultimately liver transplantation with subsequent haematopoietic stem cell transplantation (HSCT) are therapeutic options, whereby multidisciplinary management including porphyria experts is mandatory.
However, oral zinc and alefacept did not show effectiveness.
Jafarzadeh A, Pour Mohammad A, Khosravi M, Amiri S, Rasouli A, Keramati H, Goodarzi A. · Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) (2024)
Results In a total of 42 included studies, oral mini-pulse corticosteroid therapy (OMP) was the subject of six studies (14.2%).
Minocycline was the focus of five studies (11.9%), while methotrexate, apremilast, and tofacitinib each were examined in four studies (9.5%).
Antioxidants and Afamelanotide were the subjects of three studies each (7.1%).
In this review we summarize the possible use of afamelanotide in dermatology, with special emphasis on EPP and encourage including afamelanotide as a treatment option in patient care.
Polańska A, Wegner J, Nutbohm P, Staubach P, Żaba R, Dańczak-Pazdrowska A, Jenerowicz D. · Postepy dermatologii i alergologii (2024)
Its main properties are related to the enhanced production of eumelanin by agonistically binding to the melanocortin-1 receptor.
Since 2016 afamelanotide has been especially applied to treat cases of erythropoietic porphyria (EPP), where painful photosensitivity has been observed since early childhood.
The positive effect of afamelanotide in EPP administered subcutaneously improved tolerance to artificial white light and increased pain-free time spent in direct sunlight.
Bridging the gap between molecular mechanisms and therapeutic options would be a valuable reference for physicians in clinical practice.
Ju HJ, Bae JM. · Dermatology (Basel, Switzerland) (2024)
In recent years, a great advance has been made in the understanding of pathogenesis of vitiligo, and JAK inhibitors are being investigated as a new treatment.
Minimally invasive procedures such as fractional lasers or microneedling can help achieve the optimal treatment outcome when used properly.
Key messages Our review describes various treatment modalities for vitiligo based on their molecular mechanism of action.
The study shows a positive safety profile of afamelanotide, with the treatment providing an ongoing clinical benefit.
Homey B, Schelonke K, Schlegel CM, Bruch-Gerharz D, Weller K, Kiefer L, Stölzel U, Staubach-Renz P, Wegner J, Keller-Melchior R, Walker G, Bochno M, Bilbao P. · Photodermatology, photoimmunology & photomedicine (2025)
EPP patients reported a significant increase in QoL compared with baseline values (p < 0.0001) and 91.0% of patients who started treatment continue being treated.
The safety profile of afamelanotide in patients over 70 years of age is consistent with the overall patient population.
Conclusions Afamelanotide treatment was highly effective and associated with a higher QoL in EPP patients.
We suggest that future guidelines include continuous monitoring of vitamin D and a prescription for cholecalciferol in all patients with EPP, including those treated with afamelanotide.
Kluijver LG, Nekouei Shahraki M, Wagenmakers MAEM, Hanssen BE, Kuerten V, Schelonke K, Homey B, Langendonk JG. · The British journal of dermatology (2024)
Previous studies have shown that 47-63% of patients with EPP suffer from vitamin D deficiency and a high prevalence of osteoporosis.
The prevalence of vitamin D deficiency and severe deficiency remained high despite afamelanotide treatment (< 50 nmol L-1 in 71.8% of patients and < 30 nmol L-1 in 48.1%, respectively).
Afamelanotide treatment alone did not lead to a significant average increase in vitamin D levels [β = 0.5, 95% confidence interval (CI) -3.2 to 4.2].
A combination of afamelanotide implant and NB-UV-B phototherapy resulted in clinically apparent, statistically significant superior and faster repigmentation compared with NB-UV-B monotherapy.
Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M. · JAMA Dermatol (2015)
Randomized multicenter trial in non-segmental vitiligo: combination 16 mg afamelanotide + NB-UV-B (n=28) vs NB-UV-B monotherapy (n=27)
Combination superior on Vitiligo Area Scoring Index and faster face/upper-extremity repigmentation
Repigmentation at day 168: 48.6% (combination) vs 33.3% (monotherapy)
In the phase III trial, CUV039, afamelanotide treatment improved light tolerance in patients with EPP... enabled patients to spend more time in direct sunlight without pain.
Kim ES, Garnock-Jones KP. · Am J Clin Dermatol (2016)
Drug review summarizing the approved 16 mg controlled-release subcutaneous implant for EPP
Confirmatory Phase 3 trial CUV039 increased pain-free sun-exposure time and time to first phototoxicity symptoms vs placebo
Generally well tolerated; no drug-related serious adverse events; common reactions headache and implant-site reactions
Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant activities, enhances DNA repair processes and modulates inflammation.
Minder EI, Barman-Aksoezen J, Schneider-Yin X. · Clin Pharmacokinet (2017)
Pharmacokinetic/pharmacodynamic review of the first α-MSH analogue and MC1R agonist
Subcutaneous route had full bioavailability; oral and transdermal produced no measurable levels or pigmentation
Controlled-release implant is effective at lower dose than daily injections; approved by EMA in 2014 for EPP phototoxicity
Increasing numbers of case reports indicate that the unregulated use of both melanotan I and II is associated with cutaneous complications, particularly melanocytic changes in existing moles and newly emerging (dysplastic) nevi.
Habbema L, Halk AB, Neumann M, Bergman W. · Int J Dermatol (2017)
Review of risks of unregulated α-MSH analogues (melanotan I and II) used for tanning
Contrasts these with afamelanotide, the only α-MSH analogue approved for limited medical indications and 'thoroughly tested and deemed safe'
Case reports link unregulated melanotan to melanocytic changes in moles and new dysplastic nevi; four reports describe melanomas emerging from existing moles
There is randomized controlled trial (RCT) evidence for the successful use of afamelanotide in several conditions beyond erythropoietic protoporphyria, including polymorphic light eruption and vitiligo.
Wu J, Cotliar R. · J Drugs Dermatol (2021)
Review of afamelanotide (Scenesse), FDA-approved to increase pain-free sunlight exposure in adults with EPP
Dual photoprotective and anti-inflammatory effects underpin interest in other photosensitive diseases
RCT evidence in polymorphic light eruption and vitiligo; smaller studies in acne, Hailey-Hailey disease and solar urticaria